SCHEMBL2052827

SCHEMBL2052827

COCCN(CCCOc1cc2ncnc(Nc3cnn(CC(=O)Nc4cccc(F)c4)c3)c2cc1OC)CCOP(=O)(O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 6/20 0.74
FLT3 P36888 6/20 0.74
FLT4 P35916 5/20 0.74
AURKA O14965 11/20 0.60
CSF1R P07333 3/20 0.57
AURKB Q96GD4 5/20 0.56
EGFR P00533 4/20 0.52
KDR P35968 3/20 0.52
RIPK2 O43353 1/20 0.52
LCK P06239 1/20 0.52
FYN P06241 1/20 0.52
LYN P07948 1/20 0.52
RET P07949 1/20 0.52
HCK P08631 1/20 0.52
KIT P10721 1/20 0.52
PDGFRA P16234 1/20 0.52
CSNK2A2 P19784 1/20 0.52
RAB6A P20340 1/20 0.52
MST1R Q04912 1/20 0.52
MAP2K5 Q13163 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3424415 0.95 PDGFRB (0.73) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL2051886 0.93 FLT4 (0.77) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL6026663 0.93 FLT4 (0.69) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL3428300 0.92 FLT4 (0.70) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL2049374 0.90 AURKA (0.63) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL2052845 0.90 FLT4 (0.82) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL2053398 0.90 AURKA (0.61) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL3425998 0.90 AURKA (0.59) PDGFRBFLT3FLT4AURKAAURKB
SCHEMBL2050465 0.90 FLT4 (0.70) PDGFRBFLT3FLT4AURKACSF1R
SCHEMBL3429103 0.89 FLT4 (0.83) PDGFRBFLT3FLT4AURKACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 PDGFRB 1544/4885FLT3 703/4885FLT4 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.